Stephen A. Hurly - Jan 1, 2025 Form 3 Insider Report for LAVA Therapeutics NV (LVTX)

Role: Chief Executive Officer, Director
Signature: /s/ Amy Garabedian, Attorney-in-Fact
Stock symbol: LVTX
Transactions as of: Jan 1, 2025
Transactions value $: $0
Form type: 3
Date filed: 1/2/2025, 09:19 AM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	LVTX	Common Shares						5K	Jan 1, 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	LVTX	Share Options (Right to Buy)							Jan 1, 2025	Common Shares	233K	$2.35	Direct	F1, F2
holding	LVTX	Share Options (Right to Buy)							Jan 1, 2025	Common Shares	134K	$2.35	Direct	F2, F3
holding	LVTX	Share Options (Right to Buy)							Jan 1, 2025	Common Shares	360K	$2.35	Direct	F2, F4
holding	LVTX	Share Options (Right to Buy)							Jan 1, 2025	Common Shares	310K	$5.10	Direct	F5
holding	LVTX	Share Options (Right to Buy)							Jan 1, 2025	Common Shares	800K	$3.77	Direct	F6
holding	LVTX	Share Options (Right to Buy)							Jan 1, 2025	Common Shares	310K	$1.59	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Fully vested and immediately exercisable.
F2	Converted to U.S. dollars based on an exchange rate of 1.00 euro = $1.0389 (rounded to the nearest whole cent), the foreign exchange reference rate on December 31, 2024 as reported by the European Central Bank. Each option may be exercised for a price of 2.26 euros per share.
F3	33,592 of the shares underlying the option vested on December 16, 2021 and the remainder vests in 36 equal monthly installments beginning on January 16, 2022, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
F4	90,113 of the shares underlying the option vested on March 17, 2022 and the remainder vests in 36 equal monthly installments beginning on April 17, 2022, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
F5	The shares underlying the option vest in 48 equal monthly installments beginning on January 1, 2022, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
F6	The shares underlying the option vest in 48 equal monthly installments beginning on February 1, 2023, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.
F7	The shares underlying the option vest in 48 equal monthly installments beginning on February 19, 2024, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on each such vesting date.